预约演示
更新于：2026-08-19
Methohexital Sodium
美索比妥
更新于：2026-08-19
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用方式 拮抗剂 |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
7
项与 美索比妥 相关的临床试验ChiCTR2500113973
A Study on Brain Imaging and Blood Biomarkers of Non-invasive Neuromodulation Therapy for Depression Patients
NCT05655754
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
NCT04187196
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,550
项与 美索比妥 相关的文献（医药）2025-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta‐Analysis
Review
作者: Ahlmén‐Laiho, Ulla ; Saari, Tom ; Huoponen, Saara H. ; Sisa, Katrin ; Taittonen, Markku
ABSTRACT:
Background:
Electroconvulsive therapy (ECT) is a widely used treatment for depression, but the choice of the anesthetic that is used for induction may affect both clinical outcomes and the occurrence of adverse effects (AEs). Propofol and methohexital are frequently used in Finland, yet their relative impact on treatment efficacy and AEs remains uncertain.
Methods:
We conducted a systematic literature review and meta‐analysis following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic databases were searched up to January 21, 2025. Studies comparing propofol and methohexital in adult patients receiving ECT for depression and utilizing numeric scales for depression assessment were included. The primary outcome was the clinical treatment response, defined by the number of ECT sessions required to achieve remission. The secondary outcome was the variation of AEs associated with ECT between comparator groups.We included eight studies in the final analysis with 194 patients in the propofol group and 198 patients in the methohexital group. Five of the studies were randomized controlled trials and three were retrospective cohort studies. Three randomized controlled trials with 131 patients: 62 (47%) in propofol group and 69 (53%) in methohexital group were included in meta‐analysis.
Results:
The number of ECT sessions required for recovery did not differ between groups. All studies demonstrated effective alleviation of depression through ECT, regardless of anesthetic choice. However, AEs were inconsistently reported, and a comprehensive overview of the topic was not possible.
Conclusions:
Low‐quality evidence suggests equal efficacy of propofol compared to methohexital with regard to clinical remission of depression after ECT.
Systematic Review Registration:
Trial Registration: PROSPERO; CRD42024520709.
Editorial Comment:
This systematic review and meta‐analysis presents the available but limited and low‐quality evidence in this study area, and supports an interpretation that propofol and methohexital have similar efficacy when facilitating electroconfulsive therapy as treatment for depression, to relieve depression symptoms.
2025-06-01NEUROBIOLOGY OF DISEASE
Exploring potential key genes and disease mechanisms in early-onset genetic epilepsy via integrated bioinformatics analysis
Article
作者: Efthimiopoulos, Spiros ; Boulaki, Vasiliki ; Spyrou, George Μ ; Moschonas, Nicholas K
Epilepsy is a severe common neurological disease affecting all ages. Epilepsy with onset before the age of 5 years, designated early-onset epilepsy (EOE), is of special importance. According to previous studies, genetic factors contribute significantly to the pathogenesis of EOE that remains unclear and must be explored. So, a list of 229 well-selected EOE-associated genes expressed in the brain was created for the investigation of genetic factors and molecular mechanisms involved in its pathogenesis. Enrichment analysis showed that among significant pathways were nicotine addiction, GABAergic synapse, synaptic vesicle cycle, regulation of membrane potential, cholinergic synapse, dopaminergic synapse, and morphine addiction. Performing an integrated analysis as well as protein-protein interaction network-based approaches with the use of GO, KEGG, ClueGO, cytoHubba and 3 network metrics, 12 hub genes were identified, seven of which, CDKL5, GABRA1, KCNQ2, KCNQ3, SCN1A, SCN8A and STXBP1, were identified as key genes (via Venn diagram analysis). These key genes are mostly enriched in SNARE interactions in vesicular transport, regulation of membrane potential and synaptic vesicle exocytosis. Clustering analysis of the PPI network via MCODE showed significant functional modules, indicating also other pathways such as N-Glycan biosynthesis and protein N-linked glycosylation, retrograde endocannabinoid signaling, mTOR signaling and aminoacyl-tRNA biosynthesis. Drug-gene interaction analysis identified a number of drugs as potential medications for EOE, among which the non-FDA approved drugs azetukalner (under clinical development), indiplon and ICA-105665 and the FDA approved drugs retigabine, ganaxolone and methohexital.
2025-06-01JOURNAL OF ECT
A Survey of ECT Anesthesia Practice Variation in Finland
Article
作者: Sisa, Katrin ; Huoponen, Saara H. ; Taittonen, Markku ; Saari, Tom ; Huoponen, Saara H ; Ahlmén-Laiho, Ulla
Objective:
This study examines the extent of variation in anesthesia practices among Finnish neuromodulation units providing electroconvulsive therapy (ECT) and investigates recent changes within individual units.
Methods:
An electronic survey was carried out among Finnish neuromodulation units exploring staff demographics, anesthesia practices (including agents and adjuvants), patient physiology monitoring, observed adverse effects, patient follow-up times, and recent anesthesia protocol changes.
Results:
Finland has 26 neuromodulation units providing ECT, of which 18 (69%) responded to our study. The research uncovered significant differences in anesthesia practices, including induction agent choice, convulsion motor component monitoring, staff educational backgrounds, and reported adverse effects. Propofol was the most commonly used anesthetic in 14 units (78%). Three units (17%) reported using methohexital in 80%–100% of their patients, whereas in contrast, methohexital was not used at all in 10 units (56%). Electromyography seizure activity was quantitatively measured in 6 units (33%), whereas 10 units (56%) did not measure electromyography seizure activity at all. The remaining 2 units assessed seizure activity through visual observation. Headache requiring medication was the most commonly reported adverse effect, and it was reported as a frequent problem in 3 units (18%).
Conclusions:
Based on the variation in anesthesia practices identified in the study, we suggest there may be benefits to developing a national guideline for standardizing treatment.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 | |
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 鏇鏇選積鹽網範憲簾選(鏇壓艱願齋鏇鬱齋憲醖) = 餘遞製鑰廠膚獵顧鑰廠 觸夢繭積鏇膚襯鏇憲獵 (選糧鹽鏇獵糧壓繭選積, 蓋選獵範鏇齋觸鹽獵廠 ~ 築憲蓋襯築鏇憲鑰憲鬱) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 鏇鏇選積鹽網範憲簾選(鏇壓艱願齋鏇鬱齋憲醖) = 選製襯築網淵鑰壓範積 觸夢繭積鏇膚襯鏇憲獵 (選糧鹽鏇獵糧壓繭選積, 簾積遞廠願鑰鬱鹽範淵 ~ 艱製顧夢壓構範繭顧糧) 更多 | ||||||
临床4期 | 73 | 鑰鬱繭顧淵鏇鹽鹽淵鏇(蓋廠構獵鏇蓋遞鬱遞憲) = 繭顧艱選鬱願膚簾壓觸 夢憲選鹹糧鹹鹽積製獵 (鑰憲艱鑰鏇構選醖廠鏇 ) 更多 | - | 2022-09-21 | |||
鑰鬱繭顧淵鏇鹽鹽淵鏇(蓋廠構獵鏇蓋遞鬱遞憲) = 鹹積繭窪襯網範鑰繭鹹 夢憲選鹹糧鹹鹽積製獵 (鑰憲艱鑰鏇構選醖廠鏇 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 築襯顧蓋積憲艱積願選 = 願簾構蓋網襯鬱夢壓壓 醖範鑰壓製壓觸衊憲鬱 (鑰膚衊積餘淵鏇築鹽夢, 齋艱醖築簾遞遞膚淵齋 ~ 廠積網願壓窪簾襯艱觸) 更多 | - | 2019-03-13 | ||
(Propofol) | 築襯顧蓋積憲艱積願選 = 齋顧鹹網網鹽獵鏇餘蓋 醖範鑰壓製壓觸衊憲鬱 (鑰膚衊積餘淵鏇築鹽夢, 鑰蓋願蓋衊遞壓願遞蓋 ~ 獵構網壓獵築憲壓糧獵) 更多 | ||||||
临床4期 | - | 138 | (Bilateral ECT Mecta 5000M) | 窪醖衊膚餘鬱選蓋網構(遞製衊獵鬱簾廠鑰壓構) = 壓壓膚鏇壓衊製淵網鏇 觸夢襯顧襯襯壓膚範襯 (鏇繭廠糧築淵廠餘夢窪, 6.3) 更多 | - | 2018-11-14 | |
(High-dose Unilateral ECT Mecta 5000M) | 窪醖衊膚餘鬱選蓋網構(遞製衊獵鬱簾廠鑰壓構) = 積願觸簾廠觸遞鑰遞蓋 觸夢襯顧襯襯壓膚範襯 (鏇繭廠糧築淵廠餘夢窪, 6.1) 更多 | ||||||
N/A | 20 | (Ketamine Inductions) | 糧鑰製願獵鑰艱醖築顧(餘衊蓋築襯鬱鬱範網壓) = 簾獵顧糧廠範餘獵願夢 獵網衊壓顧獵窪鏇餘範 (蓋廠醖衊鬱觸襯選範醖, 1.6) 更多 | - | 2014-12-30 | ||
(Methohexital Inductions) | 糧鑰製願獵鑰艱醖築顧(餘衊蓋築襯鬱鬱範網壓) = 築簾夢積網觸襯範築襯 獵網衊壓顧獵窪鏇餘範 (蓋廠醖衊鬱觸襯選範醖, 1.6) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 餘齋構餘範壓衊餘鑰膚(製顧齋廠鏇積鏇膚憲醖) = 襯夢範範壓製鏇壓醖築 鏇膚餘觸鑰蓋膚選糧糧 (遞齋構糧築願壓鹽淵構 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 餘齋構餘範壓衊餘鑰膚(製顧齋廠鏇積鏇膚憲醖) = 醖齋襯範製選蓋構衊蓋 鏇膚餘觸鑰蓋膚選糧糧 (遞齋構糧築願壓鹽淵構 ) | ||||||
N/A | 38 | (Ketamine) | 膚鏇壓壓願構遞醖築醖(積鏇鹽範襯廠觸襯顧製) = 鹽簾糧獵遞襯鹹築觸築 衊衊窪構遞窪鬱選製襯 (鹽鏇範觸鑰餘構遞鏇窪, 8.11) 更多 | - | 2013-08-06 | ||
(Methohexital) | 膚鏇壓壓願構遞醖築醖(積鏇鹽範襯廠觸襯顧製) = 積醖築獵網艱膚鹹蓋範 衊衊窪構遞窪鬱選製襯 (鹽鏇範觸鑰餘構遞鏇窪, 7.70) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用